Hikma Pharmaceuticals PLC
HKMPY · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.08 | -0.25 | 0.02 | -0.40 |
| FCF Yield | 1.51% | 4.07% | 2.42% | 4.89% |
| EV / EBITDA | 15.75 | 21.48 | 14.90 | 28.20 |
| Quality | ||||
| ROIC | 5.00% | 4.92% | 7.57% | 2.76% |
| Gross Margin | 43.73% | 39.14% | 48.18% | 43.37% |
| Cash Conversion Ratio | 0.68 | 2.42 | 0.88 | 5.86 |
| Growth | ||||
| Revenue 3-Year CAGR | 9.71% | 9.70% | 9.30% | 8.28% |
| Free Cash Flow Growth | -58.62% | 74.22% | -47.85% | 213.15% |
| Safety | ||||
| Net Debt / EBITDA | 2.78 | 3.62 | 2.44 | 4.60 |
| Interest Coverage | 6.42 | 5.39 | 7.98 | 2.93 |
| Efficiency | ||||
| Inventory Turnover | 0.86 | 0.91 | 0.87 | 0.91 |
| Cash Conversion Cycle | 103.46 | 115.15 | 97.47 | 113.82 |